biuro@scopefluidics.com +48 22 376 21 14

About
Team
Our offer
Knowledge base
News
Investor relations
Career
Contact

biuro@scopefluidics.com +48 22 376 21 14

About
Team
Our offer
Knowledge base
News
Investor relations
Career
Contact

biuro@scopefluidics.com +48 22 376 21 14

RAPORT ESPI 35/2020 | 16-10-2020 | Decyzja w sprawie wyboru nowego projektu realizowanego przez Scope Fluidics

Previous PostRAPORT ESPI 34/2020 | 08-10-2020 | Rozpoczęcie badań prewalidacyjnych panelu PCR|ONE SARS-CoV-2 na próbkach klinicznych w zewnętrznym laboratorium szpitalnymNext PostRAPORT ESPI 36/2020 | 19-10-2020 | Prof. Carl Wittwer nowym członkiem Komitetu Doradczego

0Shares

Related Posts

Scope Fluidics establishes an international Clinical Advisory Board for the BACTEROMIC system

SCOPE FLUIDICS0

Scope Fluidics reports positive results for the UNI FAST Panel and the PBC Panel

SCOPE FLUIDICS0

Scope Fluidics appoints transaction advisor for the BACTEROMIC system

SCOPE FLUIDICS0

CONTACT US

Tel. +48 22 376 21 14
Email: biuro@scopefluidics.com

Address

Ogrodowa 58
9th floor
00-876 Warsaw

KRS: 0000668408

NIP: 527-264-59-89

REGON: 142-754-170

LEI: 259400EUNFX4E2BEHU15

Company registered in the District Court for the Capital City of Warsaw in Warsaw, XII Commercial Division of the National Court Register.

Share capital: PLN 316 827,10 fully paid up

Bank Account Number: 03 2490 0005 0000 4520 3046 2136

Terms of use

Cookies Policy

Information clause

Whistleblower Protection

Scope Fluidics 2021 ® All rights reserved